This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Cellectar Biosciences, Inc.
Drug Names(s): I-131-CLR1404, 131I-CLR-1404, CLR 131
131I-CLR-1404 (HOT, a radiolabeled compound) is a small-molecule, broad-spectrum, cancer targetedradiopharmaceutical comprised of asmall quantity of COLD, a cancer-targeted chemotherapy that inhibits the phosphatidylinosotol 3-kinase (PI3K)/Akt survival pathway, acting as a cancer-targeted delivery and retention vehicle, and incorporating a cytotoxic dose of radiotherapy (in the form of iodine-131, a radioisotope that is already in common use to treat thyroid and other cancer types).
HOT, 18-(p-[131I]iodophenyl) octadecyl phosphocholine, is part of a trio of similar drugs along with LIGHT and COLD. COLD was deliberately designed to contain iodine (in the form of the stable, non-radioactive isotope, 127-I), thus enabling additional, distinct products differing only with respect to the form of iodine they contain - HOT contains short-lived radioactive 131-I, which has a radiation half-life of eight days, and LIGHT contains even more short-lived 124-I.
The in vivo efficacy of COLD is believed to be at least in part the result of selective inhibition of the apoptosis-suppressing PI3K/Akt signaling pathway in cancer cells.
Deal Structure: 131I-CLR-1404 is under license by Cellectar from the University of Michigan.
In April 2011, Novelos completed its acquisition of Cellectar in a stock-for-stock transaction.
In February 2014, Novelos announced that its corporate name will now be known as Cellectar Biosciences, Inc. The companys shares will start trading under its new name and stock ticker symbol, CLRB.
Additional information available to subscribers only: